Login to Your Account



Pharma: Other News To Note


Tuesday, May 15, 2012
• Stiefel, of Research Triangle Park, N.C., part of GlaxoSmithKline plc, said the FDA approved a new drug application for Fabior (tazarotene) foam 0.1 percent, a topical formulation of a retinoid to treat acne vulgaris in patients 12 years and older.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription